Cargando…

Fractional flow reserve versus angiography in guiding management to optimize outcomes in non–ST-elevation myocardial infarction (FAMOUS-NSTEMI): Rationale and design of a randomized controlled clinical trial()

BACKGROUND: In patients with acute non–ST-elevation myocardial infarction (NSTEMI), coronary arteriography is usually recommended; but visual interpretation of the angiogram is subjective. We hypothesized that functional assessment of coronary stenosis severity with a pressure-sensitive guide wire (...

Descripción completa

Detalles Bibliográficos
Autores principales: Berry, Colin, Layland, Jamie, Sood, Arvind, Curzen, Nick P., Balachandran, Kanarath P., Das, Raj, Junejo, Shahid, Henderson, Robert A., Briggs, Andrew H., Ford, Ian, Oldroyd, Keith G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mosby 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3807653/
https://www.ncbi.nlm.nih.gov/pubmed/24093845
http://dx.doi.org/10.1016/j.ahj.2013.07.011
_version_ 1782288497248305152
author Berry, Colin
Layland, Jamie
Sood, Arvind
Curzen, Nick P.
Balachandran, Kanarath P.
Das, Raj
Junejo, Shahid
Henderson, Robert A.
Briggs, Andrew H.
Ford, Ian
Oldroyd, Keith G.
author_facet Berry, Colin
Layland, Jamie
Sood, Arvind
Curzen, Nick P.
Balachandran, Kanarath P.
Das, Raj
Junejo, Shahid
Henderson, Robert A.
Briggs, Andrew H.
Ford, Ian
Oldroyd, Keith G.
author_sort Berry, Colin
collection PubMed
description BACKGROUND: In patients with acute non–ST-elevation myocardial infarction (NSTEMI), coronary arteriography is usually recommended; but visual interpretation of the angiogram is subjective. We hypothesized that functional assessment of coronary stenosis severity with a pressure-sensitive guide wire (fractional flow reserve [FFR]) would have additive diagnostic, clinical, and health economic utility as compared with angiography-guided standard care. METHODS AND DESIGN: A prospective multicenter parallel-group 1:1 randomized controlled superiority trial in 350 NSTEMI patients with ≥1 coronary stenosis ≥30% severity (threshold for FFR measurement) will be conducted. Patients will be randomized immediately after coronary angiography to the FFR-guided group or angiography-guided group. All patients will then undergo FFR measurement in all vessels with a coronary stenosis ≥30% severity including culprit and nonculprit lesions. Fractional flow reserve will be disclosed to guide treatment in the FFR-guided group but not disclosed in the “angiography-guided” group. In the FFR-guided group, an FFR ≤0.80 will be an indication for revascularization by percutaneous coronary intervention or coronary artery bypass surgery, as appropriate. The primary outcome is the between-group difference in the proportion of patients allocated to medical management only compared with revascularization. Secondary outcomes include the occurrence of cardiac death or hospitalization for myocardial infarction or heart failure, quality of life, and health care costs. The minimum and average follow-up periods for the primary analysis are 6 and 18 months, respectively. CONCLUSIONS: Our developmental clinical trial will address the feasibility of FFR measurement in NSTEMI and the influence of FFR disclosure on treatment decisions and health and economic outcomes.
format Online
Article
Text
id pubmed-3807653
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Mosby
record_format MEDLINE/PubMed
spelling pubmed-38076532013-10-25 Fractional flow reserve versus angiography in guiding management to optimize outcomes in non–ST-elevation myocardial infarction (FAMOUS-NSTEMI): Rationale and design of a randomized controlled clinical trial() Berry, Colin Layland, Jamie Sood, Arvind Curzen, Nick P. Balachandran, Kanarath P. Das, Raj Junejo, Shahid Henderson, Robert A. Briggs, Andrew H. Ford, Ian Oldroyd, Keith G. Am Heart J Trial Design BACKGROUND: In patients with acute non–ST-elevation myocardial infarction (NSTEMI), coronary arteriography is usually recommended; but visual interpretation of the angiogram is subjective. We hypothesized that functional assessment of coronary stenosis severity with a pressure-sensitive guide wire (fractional flow reserve [FFR]) would have additive diagnostic, clinical, and health economic utility as compared with angiography-guided standard care. METHODS AND DESIGN: A prospective multicenter parallel-group 1:1 randomized controlled superiority trial in 350 NSTEMI patients with ≥1 coronary stenosis ≥30% severity (threshold for FFR measurement) will be conducted. Patients will be randomized immediately after coronary angiography to the FFR-guided group or angiography-guided group. All patients will then undergo FFR measurement in all vessels with a coronary stenosis ≥30% severity including culprit and nonculprit lesions. Fractional flow reserve will be disclosed to guide treatment in the FFR-guided group but not disclosed in the “angiography-guided” group. In the FFR-guided group, an FFR ≤0.80 will be an indication for revascularization by percutaneous coronary intervention or coronary artery bypass surgery, as appropriate. The primary outcome is the between-group difference in the proportion of patients allocated to medical management only compared with revascularization. Secondary outcomes include the occurrence of cardiac death or hospitalization for myocardial infarction or heart failure, quality of life, and health care costs. The minimum and average follow-up periods for the primary analysis are 6 and 18 months, respectively. CONCLUSIONS: Our developmental clinical trial will address the feasibility of FFR measurement in NSTEMI and the influence of FFR disclosure on treatment decisions and health and economic outcomes. Mosby 2013-10 /pmc/articles/PMC3807653/ /pubmed/24093845 http://dx.doi.org/10.1016/j.ahj.2013.07.011 Text en © 2013 The Authors https://creativecommons.org/licenses/by-nc-nd/3.0/ Open Access under CC BY-NC-ND 3.0 (https://creativecommons.org/licenses/by-nc-nd/3.0/) license
spellingShingle Trial Design
Berry, Colin
Layland, Jamie
Sood, Arvind
Curzen, Nick P.
Balachandran, Kanarath P.
Das, Raj
Junejo, Shahid
Henderson, Robert A.
Briggs, Andrew H.
Ford, Ian
Oldroyd, Keith G.
Fractional flow reserve versus angiography in guiding management to optimize outcomes in non–ST-elevation myocardial infarction (FAMOUS-NSTEMI): Rationale and design of a randomized controlled clinical trial()
title Fractional flow reserve versus angiography in guiding management to optimize outcomes in non–ST-elevation myocardial infarction (FAMOUS-NSTEMI): Rationale and design of a randomized controlled clinical trial()
title_full Fractional flow reserve versus angiography in guiding management to optimize outcomes in non–ST-elevation myocardial infarction (FAMOUS-NSTEMI): Rationale and design of a randomized controlled clinical trial()
title_fullStr Fractional flow reserve versus angiography in guiding management to optimize outcomes in non–ST-elevation myocardial infarction (FAMOUS-NSTEMI): Rationale and design of a randomized controlled clinical trial()
title_full_unstemmed Fractional flow reserve versus angiography in guiding management to optimize outcomes in non–ST-elevation myocardial infarction (FAMOUS-NSTEMI): Rationale and design of a randomized controlled clinical trial()
title_short Fractional flow reserve versus angiography in guiding management to optimize outcomes in non–ST-elevation myocardial infarction (FAMOUS-NSTEMI): Rationale and design of a randomized controlled clinical trial()
title_sort fractional flow reserve versus angiography in guiding management to optimize outcomes in non–st-elevation myocardial infarction (famous-nstemi): rationale and design of a randomized controlled clinical trial()
topic Trial Design
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3807653/
https://www.ncbi.nlm.nih.gov/pubmed/24093845
http://dx.doi.org/10.1016/j.ahj.2013.07.011
work_keys_str_mv AT berrycolin fractionalflowreserveversusangiographyinguidingmanagementtooptimizeoutcomesinnonstelevationmyocardialinfarctionfamousnstemirationaleanddesignofarandomizedcontrolledclinicaltrial
AT laylandjamie fractionalflowreserveversusangiographyinguidingmanagementtooptimizeoutcomesinnonstelevationmyocardialinfarctionfamousnstemirationaleanddesignofarandomizedcontrolledclinicaltrial
AT soodarvind fractionalflowreserveversusangiographyinguidingmanagementtooptimizeoutcomesinnonstelevationmyocardialinfarctionfamousnstemirationaleanddesignofarandomizedcontrolledclinicaltrial
AT curzennickp fractionalflowreserveversusangiographyinguidingmanagementtooptimizeoutcomesinnonstelevationmyocardialinfarctionfamousnstemirationaleanddesignofarandomizedcontrolledclinicaltrial
AT balachandrankanarathp fractionalflowreserveversusangiographyinguidingmanagementtooptimizeoutcomesinnonstelevationmyocardialinfarctionfamousnstemirationaleanddesignofarandomizedcontrolledclinicaltrial
AT dasraj fractionalflowreserveversusangiographyinguidingmanagementtooptimizeoutcomesinnonstelevationmyocardialinfarctionfamousnstemirationaleanddesignofarandomizedcontrolledclinicaltrial
AT junejoshahid fractionalflowreserveversusangiographyinguidingmanagementtooptimizeoutcomesinnonstelevationmyocardialinfarctionfamousnstemirationaleanddesignofarandomizedcontrolledclinicaltrial
AT hendersonroberta fractionalflowreserveversusangiographyinguidingmanagementtooptimizeoutcomesinnonstelevationmyocardialinfarctionfamousnstemirationaleanddesignofarandomizedcontrolledclinicaltrial
AT briggsandrewh fractionalflowreserveversusangiographyinguidingmanagementtooptimizeoutcomesinnonstelevationmyocardialinfarctionfamousnstemirationaleanddesignofarandomizedcontrolledclinicaltrial
AT fordian fractionalflowreserveversusangiographyinguidingmanagementtooptimizeoutcomesinnonstelevationmyocardialinfarctionfamousnstemirationaleanddesignofarandomizedcontrolledclinicaltrial
AT oldroydkeithg fractionalflowreserveversusangiographyinguidingmanagementtooptimizeoutcomesinnonstelevationmyocardialinfarctionfamousnstemirationaleanddesignofarandomizedcontrolledclinicaltrial